Febuxostat is a selective inhibitor of xanthine oxidase that is used for the treatment of hyperuricaemia in patients with gout. An isocratic liquid chromatographic method was developed and validated for the determination of febuxostat. Chromatographic separation was achieved on a C18 column using sodium acetate buffer ( pH 4.0) -acetonitrile (40:60, v/v), with a flow rate 1.2 mL/min (ultraviolet detection at 254 nm). Linearity was observed in the concentration range of 0.1 -200 mg/mL (R 2 5 0.9999) with a linear regression equation of y 5 21148x -2025.1. The limit of quantification was found to be 0.0783 mg/mL and the limit of detection was found to be 0.0257 mg/mL. Febuxostat was subjected to stress conditions of degradation in aqueous solutions, including acidic, alkaline, oxidation, photolysis and thermal degradation. The forced degradation studies were performed by using sodium hydroxide, hydrochloric acid, hydrogen peroxide and thermal and ultraviolet radiation. Febuxostat is more sensitive toward acidic conditions than oxidation and very resistant toward alkaline, thermal and photolytic degradations. The method was validated as per the guidelines of the International Conference on Harmonization. The intra-day and interday precision (relative standard deviation) was found to be 0.29 -0.41 and 0.63 -0.76, respectively. The method is simple, specific, precise, robust and accurate for the determination of febuxostat in pharmaceutical dosage forms (tablets).
Introduction
Febuxostat (FBX) is a urate lowering drug and an inhibitor of xanthine oxidase that is indicated for use in the treatment of hyperuricemia and chronic gout. It is a non-purine selective inhibitor of xanthine oxidase (1) . It works by noncompetitively blocking the molybdenum pterin center, which is the active site on xanthine oxidase. Xanthine oxidase is needed to successively oxidize both hypoxanthine and xanthine to uric acid. Hence, FBX inhibits xanthine oxidase, therefore reducing the production of uric acid. FBX inhibits both oxidized and reduced forms of xanthine oxidase, because FBX cannot easily be displaced from the molybdenum pterin site (2 -5) . FBX ( Figure 1 ) is a non-hygroscopic, white crystalline powder that is freely soluble in dimethylformamide, soluble in dimethylsulfoxide, sparingly soluble in ethanol, slightly soluble in methanol and acetonitrile and practically insoluble in water. Chemically, it is 2-[3-cyano-4-(2-methylpropoxy) phenyl]-4-methylthiazole-5-carboxylic acid, with molecular weight 316.38 (6) . Several analytical techniques have been developed for the determination of FBX in biological fluids, including reversed-phase highperformance liquid chromatography (RP-HPLC) (7), liquid chromatography -mass spectrometry (LC -MS) (8) and ultraperformance liquid chromatography (UPLC) -MS (9 -10). The xanthine inhibitors have been analyzed by thin-layer chromatography (TLC) (11) , HPLC (12) and spectrophotometric (13 -16) methods in pharmaceutical formulations. The impurity profile and related substances have also been studied by LCtandem mass spectrometry (MS-MS) (17) and HPLC (18) . Because no stability-indicating method has been reported, a simple, rapid, precise, accurate and robust stability-indicating liquid chromatographic method has been developed for the determination of FBX in tablets and validated according to International Conference on Harmonization (ICH) guidelines (19) .
Experimental
Reagents and solutions FBX standard (no less than 99.0% purity) was obtained from Torrent Pharmaceuticals (India). Acetonitrile (HPLC grade), sodium hydroxide (NaOH), hydrochloric acid (HCl) and hydrogen peroxide (H 2 O 2 ) were obtained from Merck (India). FBX is available in different amounts with brand names such as Febugood (Torrent Pharmaceuticals; label claim: 40 mg), Febutaz (Sun Pharmaceuticals Industries; label claim: 80 mg) and Zurig (Zydus Cadila Health Care; label claim: 40 mg). All chemicals were of analytical grade and used as received.
Sodium acetate buffer solution
The buffer solution ( pH 4.0) was prepared by mixing 28.6 mL of glacial acetic acid with 10 mL of 50% (w/v) NaOH in a 1,000 mL volumetric flask, dissolving and diluting to volume with HPLC-grade water.
FBX stock standard solution
The FBX stock solution (1,000 mg/mL) was prepared by accurately weighing 25 mg of FBX in a 25 mL volumetric flask and completing to volume with mobile phase. Working solutions for HPLC injections were prepared on a daily basis from the stock solution with a mobile phase containing sodium acetate buffer and acetonitrile (40:60, v/v). Solutions were filtered through a 0.45 mm membrane filter before injection.
HPLC instrumentation and conditions
Chromatographic separation was achieved by using a Shimadzu model CBM-20A/20 Elite HPLC system, equipped with an SPD M20A prominence photodiode array (PDA) detector with a C18 column (250 Â 4.6 mm i.d., 5 mm particle size) maintained at 258C. Isocratic elution was performed using sodium acetate buffer ( pH 4.0) and acetonitrile (40:60, v/v). The overall run time was 10 min and the flow rate was 1.2 mL/min. Twenty microliters of the sample were injected into the HPLC system.
Stress studies
Stress studies were performed to evaluate the stability-indicating properties and the specificity of the method (20) . All samples were diluted with the mobile phase to a final concentration of 100 mg/mL and filtered before injection.
Acidic conditions
Acidic degradation was performed by preparing the drug solution (1 mg/mL) in 0.1 N HCl. The resulting solution was refluxed for 30 min at 808C and cooled, and then the stressed sample was neutralized and diluted with mobile phase according to the requirement before injection into the HPLC system.
Alkaline conditions
Alkaline degradation was performed by preparing the drug solution (1 mg/mL) in 0.1 N NaOH. The resulting solution was refluxed for 30 min at 808C and cooled, and then the stressed sample was neutralized and diluted with mobile phase according to the requirement before injection into the HPLC system.
Oxidation conditions
Oxidation degradation was performed by preparing the drug solution (1 mg/mL) in 3% H 2 O 2 . The resulting solution was refluxed for 30 min at 808C and cooled, and then the stressed sample was diluted with mobile phase according to the requirement before injection into the HPLC system.
Thermal stress studies
For thermal stress testing, the drug solution (1 mg/mL) was heated in a thermostat at 808C for 30 min, cooled and used.
Photo degradation studies
The drug solution (1 mg/mL) for photostability testing was exposed to an ultraviolet (UV) light chamber (365 nm) for 4 h and analyzed.
Method validation

Linearity
The linearity of the method was established by preparing a calibration curve. For this, a series of drug solutions was prepared (0.1-200 mg/mL) from the stock solution of the drug with the mobile phase and 20 mL of each solution was injected into the HPLC system. The peak area of the chromatograms was recorded. The calibration curve was plotted by measuring the concentration on the x-axis and the corresponding peak area on the y-axis. The data were treated with the linear regression analysis method.
Precision
The intra-day precision of the assay method was evaluated by conducting nine independent assays of a test sample of FBX at three concentration levels (10, 20 and 50 mg/mL) (n ¼ 3) against a qualified reference standard. The relative standard deviation (RSD) of three assay values at three different concentration levels was calculated. The inter-day precision study was performed on three different days; i.e., Day 1, Day 2 and Day 3, at three different concentration levels (10, 20 and 50 mg/mL); each value is the average of three determinations (n ¼ 3). The RSD of three assay values on three different days was calculated.
Accuracy
The accuracy of the assay method was evaluated in triplicate at three concentration levels (80, 100 and 120%) and the percentage recoveries were calculated. Standard addition and recovery experiments were conducted to determine the accuracy of the method for the quantification of FBX in the drug product. The study was conducted in triplicate at 18, 20 and 22 mg/mL. The percentage recovery in each case was calculated.
Sensitivity/limit of quantification and limit of detection The limit of quantification (LOQ) and limit of detection (LOD) were based on the standard deviation (SD) of the response and the slope of the constructed calibration curve (n ¼ 3), as described in ICH guideline Q2 (R1) (20) . The sensitivity of the method was established with respect to the LOD and LOQ for FBX. LOD and LOQ were established by the following slope method:
Robustness
The robustness of the assay method was established by introducing small changes into the HPLC conditions, which included wavelength (252 and 256 nm), percentage of acetonitrile in the mobile phase (58 and 62%) and flow rate (1.1 and 1.3 mL/ min). The robustness of the method was studied by using six replicates at an FBX concentration level of 20 mg/mL.
Solution stability and mobile phase stability
The solution stability of FBX in the assay method was conducted by leaving both the sample and reference standard solutions in tightly capped volumetric flasks at room temperature for 48 h. The same sample solutions were assayed at 12-h intervals over the study period. The stability of the mobile phase was also assessed by assaying the freshly prepared sample solutions against freshly prepared reference standard solutions at 12-h intervals up to 48 h. The prepared mobile phase remained constant during the study period. The RSD of the FBX assay was calculated for the mobile phase and solution stability experiments. An additional study was conducted using the stock solution by storing it in a tightly capped volumetric flask at 48C.
Assay of tablet formulation
Twenty tablets from each brand (Febugood, Febutaz and Zurig) were procured from a medical store, weighed and crushed to a fine powder. Powder equivalent to 25 mg FBX from the preceding brands was accurately weighed and dissolved in the mobile phase in different 25 mL volumetric flasks. The contents of the volumetric flasks were sonicated for 30 min and filtered through a 0.45 mm membrane filter before injection.
Results and Discussion
No stability-indicating LC method has been reported for FBX. A detailed study comparing the previously published methods with the present method is discussed in Table I . Satisfactory resolution was achieved with the use of a mixture of sodium acetate buffer and acetonitrile (40:60, v/v) and a C18 column was adopted for the analysis because it provided better separation of the analytes. UV detection was conducted at 254 nm (PDA detector).
The present stability-indicating method for the determination of FBX in pharmaceutical formulations is specific because the drug peak was well separated, even in the presence of degradation products. Overall, the data demonstrated that the excipients and the degradation products did not interfere with the FBX peak, indicating the selectivity of the method. The complete separation of the analytes was accomplished in less than 10 min, and the method can successfully be applied to perform long-term and accelerated stability studies of FBX formulations.
HPLC method development and optimization
Initially, the pure drug sample solutions were analyzed using a mobile phase consisting of water-acetonitrile (40:60, v/v) at a flow rate of 0.8 mL/min. Under these conditions, a sharp peak was observed at 2.304 min with fronting, which continued even when the mobile phase composition was changed to 50:50 or 60:40 or the flow rate was changed to 1.2 mL/min. Finally the mobile phase was completely changed to sodium acetate buffer ( pH 4.0) -acetonitrile (40:60, v/v) with a flow rate of 1.2 mL/min, under which peaks were well resolved with good symmetry and a retention time of 3.49 min. Therefore, the mobile phase containing sodium acetate buffer ( pH 4.0) -acetonitrile (40:60, v/v) was chosen because it provided the best chromatographic response for the entire study.
Method validation
System suitability
The system suitability test was performed to ensure that the complete testing system was suitable for the intended application. The parameters measured were peak area, retention time, tailing factor, capacity factor and theoretical plates. In all measurements, the peak area varied less than 2.0% and the average retention time was 3.47 + 0.02 min. The capacity factor was more than 2, theoretical plates were 9,549 (more than 2,000) and the tailing factor was 1.21 (less than 2) for the FBX peak.
The LOQ was found to be 0.0783 mg/mL and the LOD was found to be 0.0257 mg/mL.
Linearity
The typical chromatograms for FBX obtained from the bulk and extracted marketed formulations are shown in Figures 2A-2C . The calibration curve for FBX was linear over the concentration range of 0.1 -200 mg/mL. The data for the peak area of the drug corresponding to the concentration was treated by linear regression analysis (Table II) and the regression equation for the calibration curve was found to be y ¼ 21148x -2025.1, with a correlation coefficient of 0.9999, which is nearly equal to unity. The RSD range was 0.257 -0.628%.
Precision
The precision of the method was determined by repeatability (intra-day precision) and intermediate precision (inter-day precision) of the FBX standard solutions. Repeatability was calculated by assaying three samples of each at three different concentration levels (10, 20 and 50 mg/mL) on the same day. The inter-day precision was calculated by assaying three samples at three different concentration levels (10, 20 and 50 mg/mL) on three different days. The RSD ranges were obtained as 0.29-0.41 and 0.63 -0.76 for intra-day and inter-day precision studies, respectively (Table III) . Because the stability of standard solutions can also affect the robustness of analytical methods, the stability of standard solutions of the drug substance used in this method was tested over a long period of time (48 h). One portion of a standard solution was kept at room temperature and the other portion was stored under refrigeration at approximately 48C, and the contents of these solutions were regularly compared with those of freshly prepared solutions. No change in drug concentrations were observed for solutions stored under refrigeration. However, it is recommended that the sample and standard solutions must be freshly prepared in amber-colored flasks to protect from light.
Accuracy
The accuracy of the method was proved by the recovery studies. A known amount of FBX standard (10 mg/mL) was added to aliquots of sample solutions and then diluted to yield total concentrations of 18, 20 and 22 mg/mL, as described in Table III . The assay was repeated over three consecutive days. The resultant RSD was in the range 0.19 -0.69 (,2.0%) with recovery of 98.39-99.45%.
Robustness
The robustness of an analytical procedure refers to its ability to remain unaffected by small and deliberate variations in method parameters, and provides an indication of its reliability for routine analysis (20) . The robustness of the method was evaluated by assaying the same sample under different analytical conditions that had been deliberately changed from the original condition. The detection wavelengths were set at 252 and 256 nm (+2 nm), the ratios of the percentage of sodium acetate buffer ( pH 4.0)-acetonitrile in the mobile phase were applied at 42:58 and 38:62 (+2%, v/v) and the flow rates were set at 1.1 and 1.3 mL/min (+0.1 mL/min). The results (Table IV) from the assay of the test solutions were not affected by varying the conditions, and were in accordance with the results for original conditions. The RSD value of the assay, determined for the same sample under original conditions and robustness conditions, was less than 2.0% (0.77 -1.06), indicating that the developed method was robust.
Selectivity/specificity
The specificity of the developed method was determined by injecting sample solutions (10 mg/mL), which were prepared by forcibly degrading under such stress conditions as heat, light, oxidative agents, acidity and basity under the proposed chromatographic conditions. The stability-indicating capability of the method was established from the separation of the FBX peak from the degraded samples. The degradation of FBX was found to be very similar for both tablets and standards. Typical chromatograms that were obtained following the assay of stressed samples are shown in Figures 3A -3E .
Solution stability and mobile phase stability
The RSD of the assay of FBX from the solution stability (0.1016) and mobile phase stability (0.4076) experiments was within 2% (Table V) . The results of the solution and mobile phase stability experiments confirm that the sample solutions and mobile phase used during the assays were stable up to 48 h at room temperature and up to three months at 48C.
Analysis of commercial formulations (tablets)
The proposed method was applied for the determination of FBX in tablets (Febugood, Febutaz and Zurig) and the results show 98.55 -98.98% recovery (Table VI) , which indicates that the method is selective for the assay of FBX without interference from the excipients used in these tablets. Forced degradation studies FBX standard and tablet powder were found to be quite stable under dry heat conditions. Slight decomposition was observed upon exposure of FBX drug solution to acidic (0.2%), alkaline (0.15%), oxidative (0.26%), thermal (3.01%) and photolytic (0.16%) degradations, indicating that the drug is highly resistant toward these degradations (Table VII) . During the oxidation reaction, an extra peak was observed at 2.065 min.
Conclusion
The proposed stability-indicating HPLC method was validated according to ICH guidelines and applied for the determination of FBX in pharmaceutical dosage forms. The method was found to be accurate, precise, robust and specific, because the drug peak elution did not interfere with any degradants during the forced degradation studies; therefore, the proposed method can be successfully applied to analyze the samples during studies. 
